Health ❯ Healthcare ❯ Medical Treatments

Neurology

Alzheimer's Disease Cognitive Disorders Parkinson's Disease Dementia Migraine Dementia Therapy

Germany Rules No Added Benefit for New Alzheimer Antibodies After Major Review Finds Little Effect

The rulings could limit reimbursement for the drugs in Germany.

G-BA Finds No Added Benefit for Alzheimer’s Drug Leqembi in Germany

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

Novo Defends Semaglutide Alzheimer’s Strategy After Phase 3 Miss

Germany Rolls Out Donanemab for Early Alzheimer’s Patients

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

First Patients in Germany Receive Lecanemab for Early Alzheimer’s

EU Approves Donanemab as Second Alzheimer’s Antibody Under Tight Conditions

Leqembi Launches in Germany for Early Alzheimer’s Patients

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

Ubrogepant Shows Promise in Treating Early Migraine Symptoms

EU Approves First Alzheimer's Drug Targeting Disease Progression

EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

FDA Approves Vyalev for Advanced Parkinson's Disease Treatment

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety